Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

Stock Analysis

POAI Predictive Oncology Inc

Price (delayed)

$0.9575

Market cap

$8.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.74

Enterprise value

$7.38M

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data ...

Highlights

The EPS has soared by 52% YoY and by 25% from the previous quarter

The company's debt fell by 26% YoY and by 9% QoQ

Predictive Oncology's equity has shrunk by 104% YoY but it has increased by 28% QoQ

Predictive Oncology's quick ratio has decreased by 46% YoY

POAI's gross profit is down by 32% year-on-year and by 17% since the previous quarter

Sector: Healthcare

Industry: Medical Instruments & Supplies

Website: http://www.precisiontherapeutics.com

Peers: OFIX

Key stats

What are the main financial stats of POAI

Market

Shares outstanding

8.93M

Market cap

$8.55M

Enterprise value

$7.38M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

5.09

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

5.48

Earnings

Revenue

$1.35M

Gross profit

$660,672

Operating income

-$9.93M

Net income

-$10.89M

EBIT

-$10.89M

EBITDA

-$10.19M

Free cash flow

-$9.3M

Per share

EPS

-$1.74

EPS diluted

-$1.74

Free cash flow per share

-$1.3

Book value per share

-$0.02

Revenue per share

$0.19

TBVPS

$0.81

Balance sheet

Total assets

$5.87M

Total liabilities

$6.01M

Debt

$1.92M

Equity

-$145,796

Working capital

-$1.12M

Liquidity

Debt to equity

-13.16

Current ratio

0.76

Quick ratio

0.68

Net debt/EBITDA

0.11

Margins

EBITDA margin

-756.8%

Gross margin

49.1%

Net margin

-808.8%

Operating margin

-737.2%

Efficiency

Return on assets

-150.6%

Return on equity

-762.4%

Return on invested capital

-498%

Return on capital employed

-864.7%

Return on sales

-808.8%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

POAI stock price

How has the Predictive Oncology stock price performed over time

Intraday

-3.38%

1 week

5.8%

1 month

-12.95%

1 year

-34.42%

YTD

16.77%

QTD

-37.01%

Financial performance

How have Predictive Oncology's revenue and profit performed over time

Revenue

$1.35M

Gross profit

$660,672

Operating income

-$9.93M

Net income

-$10.89M

Gross margin

49.1%

Net margin

-808.8%

POAI's gross profit is down by 32% year-on-year and by 17% since the previous quarter

POAI's operating income is up by 26% YoY and by 9% QoQ

POAI's net income is up by 26% year-on-year and by 14% since the previous quarter

Predictive Oncology's gross margin has decreased by 24% YoY

Price vs fundamentals

How does POAI's price correlate with its fundamentals

Growth

What is Predictive Oncology's growth rate over time

Valuation

What is Predictive Oncology stock price valuation

P/E

N/A

P/B

N/A

P/S

5.09

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

5.48

The EPS has soared by 52% YoY and by 25% from the previous quarter

Predictive Oncology's equity has shrunk by 104% YoY but it has increased by 28% QoQ

The P/S is 73% lower than the 5-year quarterly average of 19.4 but 5% higher than the last 4 quarters average of 5.0

POAI's revenue is down by 17% from the previous quarter and by 10% YoY

Efficiency

How efficient is Predictive Oncology business performance

The return on assets has dropped by 63% year-on-year

The company's return on equity fell by 49% QoQ

Predictive Oncology's ROIC has decreased by 48% YoY and by 18% from the previous quarter

The ROS has increased by 18% YoY but it has decreased by 3.7% from the previous quarter

Dividends

What is POAI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for POAI.

Financial health

How did Predictive Oncology financials performed over time

The company's total assets is 2.4% lower than its total liabilities

The current ratio has declined by 48% year-on-year but it has increased by 23% since the previous quarter

Predictive Oncology's quick ratio has decreased by 46% YoY

Predictive Oncology's equity has shrunk by 104% YoY but it has increased by 28% QoQ

The debt to equity has contracted by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.